Last updated: August 19, 2026
AstraZeneca is a global biopharmaceutical company with leading positions in oncology, cardiovascular-renal-metabolic disease, respiratory medicine, immunology, and rare disease. Its commercial strength comes from a diversified product base, a large biologics portfolio, high-value oncology assets, and disciplined external dealmaking. The principal risks are concentration in a small number of blockbuster products, patent and regulatory challenges, pricing pressure, and competition from Merck, Bristol Myers Squibb, Roche, Johnson & Johnson, Eli Lilly, Novartis, Sanofi, and GSK.
AstraZeneca reported 2023 total revenue of approximately $45.8 billion. Oncology was its largest therapy area, followed by cardiovascular, renal and metabolic disease, respiratory and immunology, and rare disease through Alexion.[1]
AstraZeneca AB is the Swedish operating company within the broader AstraZeneca group. Commercial strategy, patent ownership, regulatory filings, and litigation may involve AstraZeneca PLC, AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB, MedImmune, and Alexion entities.
What is AstraZeneca's market position in 2024?
AstraZeneca ranks among the largest global innovative pharmaceutical companies by revenue, oncology presence, and late-stage pipeline depth. Its strongest position is in targeted cancer therapy and specialty medicines.
| Strategic area |
Key AstraZeneca products |
Principal competitors |
Competitive position |
| Oncology |
Tagrisso, Imfinzi, Enhertu, Lynparza, Calquence, Truqap |
Merck, Roche, Bristol Myers Squibb, Novartis, Johnson & Johnson |
Very strong |
| Cardiovascular, renal and metabolic |
Farxiga, Lokelma, Brilinta |
Eli Lilly, Novo Nordisk, Merck, Bayer |
Strong, but less dominant in obesity |
| Respiratory |
Symbicort, Breztri, Fasenra, Tezspire |
GSK, Sanofi, Regeneron, Boehringer Ingelheim |
Strong in asthma and COPD |
| Rare disease |
Ultomiris, Soliris, Strensiq, Koselugo |
Sanofi, Roche, Takeda, BioMarin |
Strong, with high biological barriers |
| Vaccines and infectious disease |
Limited compared with prior COVID-19 position |
Pfizer, Moderna, GSK, Sanofi |
Selective rather than broad |
The company’s oncology franchise is the central commercial engine. Tagrisso, Imfinzi, Enhertu, Lynparza, Calquence, and Truqap provide exposure across non-small-cell lung cancer, breast cancer, ovarian cancer, prostate cancer, hematologic malignancies, and hormone-receptor-positive breast cancer.
AstraZeneca’s acquisition of Alexion for approximately $39 billion, completed in 2021, expanded the company into complement-mediated and rare diseases.[2] The transaction reduced AstraZeneca’s dependence on oncology while adding high-margin biologics with specialized administration and manufacturing requirements.
How much revenue exposure does AstraZeneca have to key products?
AstraZeneca has a diversified portfolio, but several products account for a material share of sales.
| Product |
Active ingredient or technology |
Primary indication |
2023 approximate product sales |
Key commercial risk |
| Tagrisso |
Osimertinib |
EGFR-mutated non-small-cell lung cancer |
$5.8 billion |
Patent expiry and competing targeted therapies |
| Farxiga |
Dapagliflozin |
Diabetes, heart failure, chronic kidney disease |
$5.4 billion |
Generic entry and SGLT2 competition |
| Imfinzi |
Durvalumab |
Multiple cancers |
$4.2 billion |
Biosimilar and checkpoint-inhibitor competition |
| Symbicort |
Budesonide/formoterol |
Asthma and COPD |
$3.1 billion |
Generic inhaler competition |
| Calquence |
Acalabrutinib |
B-cell malignancies |
Approximately $2.5 billion |
BTK competition from Imbruvica and Brukinsa |
| Fasenra |
Benralizumab |
Severe eosinophilic asthma |
Approximately $1.5 billion |
Dupixent and Nucala competition |
| Lynparza |
Olaparib |
BRCA-associated and other cancers |
Approximately $2.8 billion, including collaboration economics |
PARP-class competition and label restrictions |
| Ultomiris |
Ravulizumab |
Complement-mediated rare diseases |
Approximately $3.1 billion |
Biosimilar and next-generation complement agents |
Reported sales depend on whether AstraZeneca reports gross product sales, collaboration revenue, or net revenue after partner economics. The figures above are rounded and based primarily on AstraZeneca’s 2023 annual reporting.[1]
Tagrisso and Farxiga are particularly important because they are small-molecule products exposed to traditional generic substitution. Imfinzi, Fasenra, Ultomiris, and other antibody products face a slower biosimilar pathway, but they remain exposed to formulary pressure, therapeutic substitution, and competing biologics.
What patents protect AstraZeneca's leading products?
AstraZeneca uses several overlapping forms of protection: composition-of-matter patents, polymorph and salt patents, formulation patents, manufacturing patents, combination patents, dosing patents, and method-of-use patents.
Tagrisso patent estate
Tagrisso contains osimertinib, an irreversible EGFR tyrosine kinase inhibitor. Its central protection is based on the active chemical compound and related therapeutic uses.
A representative U.S. patent is U.S. Patent No. 9,266,951, assigned to AstraZeneca, with an Orange Book-listed expiration in 2032 before any applicable adjustment or pediatric extension.[3] AstraZeneca also has later patents and regulatory exclusivity associated with specific uses and formulations.
Tagrisso’s patent position is strong because:
- The product has a differentiated mutation-specific mechanism.
- The product is used in adjuvant and metastatic settings.
- Later clinical data support additional method-of-use claims.
- Generic applicants must address multiple listed patents through the Abbreviated New Drug Application process.
The principal weakness is that a generic entrant can challenge composition or method patents through Paragraph IV certification. A successful challenge to a core patent could accelerate entry before the full end of the listed patent term.
Farxiga patent estate
Farxiga contains dapagliflozin, an SGLT2 inhibitor. The product’s early composition patent protection is weaker than Tagrisso’s because generic companies have already pursued U.S. challenges and regulatory review.
U.S. Patent No. 6,414,126 is an early dapagliflozin-related patent and has expired.[4] Later patents cover specific formulations, combinations, and methods of treatment. AstraZeneca has relied heavily on regulatory exclusivity, pediatric provisions, litigation settlements, and additional cardiovascular and renal indications to extend the product’s commercial life.
Farxiga is exposed to:
- Generic substitution after expiration of enforceable listed patents.
- Competition from Jardiance, marketed by Boehringer Ingelheim and Eli Lilly.
- Reimbursement pressure across diabetes, heart failure, and kidney disease.
- Differences between patent protection for the molecule and protection for specific indications.
The product has meaningful clinical differentiation in heart failure and chronic kidney disease, but those indications do not eliminate generic-entry risk once the relevant patents are invalidated or expire.
Symbicort formulation and device protection
Symbicort combines budesonide and formoterol in an inhaled formulation. Its protection has involved formulation, dose, delivery-device, and method-of-use claims rather than only a conventional small-molecule composition patent.
Inhaled products create additional barriers because an abbreviated application must demonstrate pharmaceutical equivalence and, depending on the product and regulatory pathway, comparable device performance and bioequivalence. Those requirements can delay practical competition even after certain patents expire.
The strategic weakness is that U.S. inhaled products have attracted increasing generic and authorized-generic activity. AstraZeneca’s revenue protection therefore depends on device complexity, brand loyalty, payer contracting, and market share rather than patents alone.
Imfinzi, Ultomiris, and biologic protection
Imfinzi contains durvalumab, an anti-PD-L1 monoclonal antibody. Ultomiris contains ravulizumab, a long-acting complement C5 inhibitor. These products are biologics and do not use the same Orange Book listing system as small-molecule drugs.
The principal U.S. barriers include:
- Twelve-year reference-product exclusivity under the Biologics Price Competition and Innovation Act.
- Purple Book reference-product status.
- Composition, epitope, formulation, dosing, and manufacturing patents.
- Clinical development requirements for biosimilar applicants.
- Complex cell-line, purification, and analytical comparability requirements.
Biologic exclusivity does not prevent patent litigation. A biosimilar sponsor can file a license application and challenge patents under the BPCIA patent dance and related litigation procedures. Manufacturing know-how can be as important as the published patent estate because biosimilar developers must reproduce a complex biological product consistently.
When do AstraZeneca's major products lose exclusivity?
The practical loss-of-exclusivity date depends on the enforceable patent claims, pediatric extensions, regulatory exclusivity, settlement agreements, and the outcome of Paragraph IV or BPCIA litigation.
| Product |
Primary protection type |
General exclusivity risk |
| Tagrisso |
Composition and use patents |
Early-to-mid 2030s risk profile in the U.S., subject to listed patents and litigation |
| Farxiga |
Composition, formulation, combination, and use patents |
Earlier generic risk than Tagrisso; later patents remain commercially important |
| Symbicort |
Formulation, device, and use patents |
Generic inhaler competition has already developed in some markets |
| Imfinzi |
Biologic exclusivity and antibody/use patents |
Biosimilar risk is later than small-molecule risk and depends on patent litigation |
| Fasenra |
Biologic exclusivity and antibody/use patents |
Biosimilar risk is moderated by biologic complexity and severe-asthma specialization |
| Ultomiris |
Biologic exclusivity, complement mechanism, formulation, and use patents |
Long-duration protection, but Soliris-to-Ultomiris switching reduces franchise durability |
The U.S. FDA Orange Book lists approved drug products and applicable patents for small molecules. The Purple Book identifies licensed biological products and reference products for biosimilar competition.[5,6] Patent expiry should therefore be analyzed product by product and jurisdiction by jurisdiction.
Which companies are challenging AstraZeneca's products?
AstraZeneca faces competition from both originator companies and generic or biosimilar manufacturers.
Oncology competitors
Merck’s Keytruda is the most important competitor to Imfinzi in checkpoint immunotherapy. Roche competes through Tecentriq and a broad diagnostics-linked oncology franchise. Bristol Myers Squibb competes through Opdivo and Yervoy. Johnson & Johnson, AbbVie, BeiGene, and other companies challenge AstraZeneca in hematology through BTK inhibitors and related targeted therapies.
In lung cancer, AstraZeneca competes against targeted EGFR therapies from Roche and Novartis, as well as antibody-drug conjugates and immunotherapy combinations from multiple developers.
Cardiovascular and metabolic competitors
Farxiga competes directly with Jardiance and indirectly with GLP-1 products from Novo Nordisk and Eli Lilly. The expansion of obesity medicines changes treatment sequencing and may affect long-term cardiovascular and metabolic prescribing, even where Farxiga retains strong heart-failure and kidney-disease utility.
Respiratory competitors
Fasenra competes with GSK’s Nucala, Sanofi and Regeneron’s Dupixent, and Teva’s Cinqair. Symbicort competes with Trelegy, Breztri, and generic budesonide/formoterol products.
Rare-disease competitors
Ultomiris and Soliris compete with ravulizumab alternatives, C5 inhibitors, proximal complement inhibitors, and disease-specific therapies. Novartis, Apellis, Roche, and other companies are expanding complement-related programs. These products may not be direct substitutes across every disease, but they can weaken pricing and reduce treatment persistence.
What is AstraZeneca's FDA regulatory and Orange Book status?
AstraZeneca’s portfolio includes small-molecule drugs, biologics, inhaled medicines, and combination products. Regulatory protection differs by category.
- Tagrisso and Farxiga are FDA-approved small-molecule products with Orange Book relevance.
- Symbicort is an inhaled combination product with formulation and device considerations.
- Imfinzi, Fasenra, and Ultomiris are biologics regulated under the Public Health Service Act.
- Biosimilar competition for biologics is governed by the BPCIA rather than the conventional ANDA Paragraph IV framework.
- New indications can generate separate regulatory exclusivity and method-of-use patent value.
A product can remain commercially strong after a composition patent expires if it has later indications, difficult formulation requirements, strong physician adoption, or a slow biosimilar pathway. Conversely, a product with several listed patents can experience rapid erosion if a court invalidates the dominant claims or a settlement permits an early launch.
How strong is AstraZeneca's patent estate?
AstraZeneca’s patent estate is strongest in oncology and rare disease, where it combines:
- New chemical entities and engineered biologics.
- Multiple disease indications.
- Combination-treatment patents.
- Biomarker-defined patient populations.
- Complex manufacturing processes.
- Long clinical-development timelines that increase the value of patent term restoration.
The estate is weaker where products depend on older molecules, standard inhaled formulations, or crowded therapeutic classes. Farxiga and Symbicort illustrate the distinction between commercial strength and patent durability. Both products have major clinical value, but their generic exposure is materially higher than that of newer biologics.
Patent quality is also uneven by jurisdiction. U.S. patents often provide the most commercially important protection, while European and Asian markets have different standards for polymorphs, dosage regimens, second medical uses, and patent-term extensions.
What licensing deals and acquisitions support AstraZeneca's strategy?
AstraZeneca has used acquisitions and partnerships to build a multi-platform portfolio.
| Transaction or relationship |
Strategic purpose |
| Alexion acquisition, 2021 |
Added rare disease, complement biology, and high-value biologics |
| Daiichi Sankyo collaboration on Enhertu |
Added a leading HER2 antibody-drug conjugate to oncology |
| Daiichi Sankyo collaboration on datopotamab deruxtecan |
Expanded antibody-drug conjugate pipeline |
| Merck collaboration on Lynparza |
Shared development and commercialization economics for PARP inhibition |
| Gracell acquisition, 2024 |
Added CAR-T technology and cell-therapy capabilities |
| Neogene acquisition |
Added T-cell receptor and cell-therapy discovery capabilities |
| Various regional licensing agreements |
Expanded access to platforms, targets, and commercial territories |
The Daiichi Sankyo relationships are strategically important because they give AstraZeneca access to antibody-drug conjugate technology without requiring full internal development of every platform component. The Alexion acquisition adds rare-disease cash flow and a specialized commercial infrastructure, but it also increases exposure to complex biologics manufacturing and payer scrutiny.
What generic and biosimilar entry risks exist for AstraZeneca?
Generic risk is highest for Farxiga, Symbicort, and other small-molecule or inhaled products. The main entry mechanisms are ANDA filings, Paragraph IV certifications, patent invalidity claims, non-infringement arguments, and settlements that establish an authorized launch date.
Biosimilar risk is highest for mature monoclonal antibodies and complement products. Biosimilar developers must address reference-product exclusivity, patent thickets, interchangeability standards, manufacturing comparability, and payer adoption.
AstraZeneca can reduce erosion through:
- New formulations and dosing schedules.
- Additional indications.
- Fixed-dose combinations.
- Pediatric extensions.
- Device improvements.
- Authorized generics.
- Contracting and patient-support programs.
- Switching patients from older products to newer franchise products.
These measures extend commercial duration but do not replace enforceable patent rights.
How does AstraZeneca compare with Merck, Roche, and GSK?
| Company |
Core strength |
AstraZeneca comparison |
| Merck |
Keytruda, vaccines, infectious disease |
Merck has greater checkpoint scale; AstraZeneca has broader targeted oncology exposure |
| Roche |
Oncology, diagnostics, biologics |
Roche has diagnostic integration; AstraZeneca has stronger recent oncology growth in selected categories |
| GSK |
Vaccines, respiratory, infectious disease |
GSK is stronger in vaccines and respiratory scale; AstraZeneca has broader oncology and rare disease exposure |
| Bristol Myers Squibb |
Oncology, immunology, cardiovascular |
BMS has major immuno-oncology and hematology assets; AstraZeneca has stronger ADC and EGFR positioning |
| Eli Lilly |
Diabetes, obesity, neuroscience |
Lilly has greater metabolic growth exposure; AstraZeneca has broader cancer and rare-disease diversification |
| Sanofi |
Immunology, vaccines, rare disease |
Sanofi is strong in Dupixent and vaccines; AstraZeneca has a more balanced oncology platform |
AstraZeneca’s strategic differentiation is its combination of oncology depth, biologics, rare disease, and external innovation. It does not lead every therapeutic class, but it has several independent growth engines.
What patent litigation affects AstraZeneca?
The material litigation categories are:
- Paragraph IV cases involving small-molecule products.
- BPCIA litigation involving biosimilars.
- ANDA disputes over formulation and device claims.
- Patent-term restoration and pediatric-extension disputes.
- License and collaboration disputes involving shared products.
- Product-liability and regulatory litigation separate from patent enforcement.
The commercial effect of litigation depends on whether the challenged patent is a core composition patent or a narrower method-of-use claim. A successful challenge to a composition patent can enable broad generic entry. A challenge limited to one indication may allow a skinny-label launch, leaving the branded product protected for other uses.
Key Takeaways
- AstraZeneca is strongest in oncology, rare disease, and specialty biologics.
- Tagrisso, Imfinzi, Farxiga, Symbicort, Calquence, and Ultomiris are central to commercial performance.
- Tagrisso has a comparatively strong long-duration patent profile, while Farxiga and Symbicort carry earlier generic-entry risk.
- Biologic products face later but potentially significant biosimilar competition.
- Alexion materially improved AstraZeneca’s rare-disease position and portfolio diversification.
- Daiichi Sankyo collaborations increased exposure to antibody-drug conjugates.
- Merck is the principal checkpoint-immunotherapy competitor; GSK is the principal respiratory competitor; Eli Lilly and Novo Nordisk are the leading metabolic challengers.
- AstraZeneca’s patent strength is highest where composition, biomarker, combination, formulation, and manufacturing claims overlap.
- The most important commercial issue is lifecycle management across multiple indications rather than reliance on a single patent expiry date.
FAQs
What is AstraZeneca AB's main business?
AstraZeneca AB is part of the AstraZeneca group, which develops and commercializes prescription medicines in oncology, cardiovascular-renal-metabolic disease, respiratory medicine, immunology, and rare disease.
Is Tagrisso protected by patents after 2030?
Yes. Tagrisso has U.S. patents listed beyond 2030, including patents associated with osimertinib and related uses. Actual generic entry depends on the enforceability of those patents, litigation results, and any settlement terms.
Can biosimilars replace Imfinzi and Ultomiris?
Biosimilars can eventually compete with biologics such as Imfinzi and Ultomiris, but entry requires FDA approval, reference-product exclusivity analysis, patent resolution, and manufacturing comparability. Substitution may be slower than for conventional tablets.
Which AstraZeneca product has the greatest generic-entry exposure?
Farxiga has substantial generic-entry exposure because it is a small-molecule product in a competitive SGLT2 class. Symbicort also faces meaningful risk because inhaled combination products can be challenged through formulation and device pathways.
Does AstraZeneca own Enhertu?
AstraZeneca co-develops and co-commercializes Enhertu with Daiichi Sankyo under a collaboration agreement. Daiichi Sankyo developed the underlying antibody-drug conjugate platform and remains a central partner in the product’s global commercialization.
References
- AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. AstraZeneca PLC.
- AstraZeneca PLC. (2021). AstraZeneca completes acquisition of Alexion. AstraZeneca PLC.
- U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,266,951: N-substituted acrylamide compounds.
- U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,414,126: C-aryl glucoside SGLT2 inhibitors.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- AstraZeneca PLC. (2024). Full-year and fourth-quarter 2023 results. AstraZeneca PLC.
- AstraZeneca PLC and Daiichi Sankyo Company, Limited. (2019). Enhertu global development and commercialization collaboration announcement.
